Enterprise Value

22.72B

Cash

1.424B

Avg Qtr Burn

-86.84M

Short % of Float

6.26%

Insider Ownership

1.29%

Institutional Own.

48.60%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CARVYKTI (cilta-cel) (ciltacabtagene autoleucel) Details
Blood cancer, Cancer, Multiple myeloma

Approved

Quarterly sales

CARVYKTI (cilta-cel) Details
Multiple myeloma, Blood cancer, Cancer

PDUFA

Approval decision

CARVYKTI (cilta-cel) Details
Multiple myeloma, Blood cancer, Cancer

PDUFA

Adcomm

Phase 3

Data readout

LB2102 Details
Cancer, Small cell lung cancer

Phase 1

Data readout

LB1901 (antiCD4) Details
Cancer, T-cell lymphoma

Failed

Discontinued